Evidence map›Paper›PMID 28827627›Full record

ArticleScientific reports2017

Glaucoma is associated with plasmin proteolytic activation mediated through oxidative inactivation of neuroserpin.

Vivek Gupta, Mehdi Mirzaei, Veer Bala Gupta, Nitin Chitranshi, Yogita Dheer, Roshana Vander Wall, Mojdeh Abbasi, Yuyi You, Roger Chung, Stuart Graham

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Neuroserpin gene therapy inhibits retinal ganglion cell apoptosis and promotes functional preservation in glaucoma.Molecular therapy : the journal of the American Society of Gene Therapy · 2023
    Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Deficiency in Neuroserpin Exacerbates CoClFrontiers in pharmacology · 2021
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Vivek GuptaFaculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia. vivek.gupta@mq.edu.au.
Mehdi MirzaeiDepartment of Chemistry and Biomolecular Sciences, Macquarie University, Sydney, Australia.
Veer Bala GuptaSchool of Medical Sciences, Edith Cowan University, Perth, Australia.
Nitin ChitranshiFaculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia.
Yogita DheerFaculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia.
Roshana Vander WallFaculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia.
Mojdeh AbbasiFaculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia.
Yuyi YouSave Sight Institute, Sydney University, Sydney, Australia.
Roger ChungFaculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia.
Stuart GrahamFaculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia.
Macquarie University · AUUniversity of Sydney · AUEdith Cowan University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuroserpin is a serine protease inhibitor that regulates the activity of plasmin and its activators in the neuronal tissues. This study provides novel evidence of regulatory effect of the neuroserpin on plasmin proteolytic activity in the retina in glaucoma. Human retinal and vitreous tissues from control and glaucoma subjects as well as retinas from experimental glaucoma rats were analysed to establish changes in plasmin and neuroserpin activity. Neuroserpin undergoes oxidative inactivation in glaucoma which leads to augmentation of plasmin activity. Neuroserpin contains several methionine residues in addition to a conserved reactive site methionine and our study revealed enhanced oxidation of Met residues in the serpin under glaucoma conditions. Met oxidation was associated with loss of neuroserpin inhibitory activity and similar findings were observed in the retinas of superoxide dismutase (SOD) mutant mice that have increased oxidative stress. Treatment of purified neuroserpin with H2O2 further established that Met oxidation inversely correlated with its plasmin inhibitory activity. Dysregulation of the plasmin proteolytic system associated with increased degradation of the extracellular matrix (ECM) proteins in the retina. Collectively, these findings delineate a novel molecular basis of plasmin activation in glaucoma and potentially for other neuronal disorders with implications in disease associated ECM remodelling.

Indexed as

AgedAged, 80 and overAnimalsDisease Models, AnimalFibrinolysinFibrinolytic AgentsGlaucomaHumansMethionineMiceNeuropeptidesNeuroserpinOxidation-ReductionRatsRetinaSerine Proteinase InhibitorsFibrinolysinFibrinolytic AgentsMethionineNeuropeptidesNeuroserpinSerine Proteinase InhibitorsSerpins

Identifiers

PMID28827627
PMCPMC5566433
OpenAlexW2745263471

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.